forward. continue a and from all for to much, very thank analysts demonstrated and grow the sustainability was of last year, fielding Therapeutics on today you questions and Twirla. investors Thank our were XXXX our we our time Agile that call. moving ability XXXX to believe This growth for joining we year you performance us about Matt,
sustainability again Twirla answered XXXX and growth. while year-over-year reducing target believe our once revenue in net support revenue, sales, Twirla growth simultaneously factory to questions We operating by demand we've expenses meaningful the demonstrating in
our XXXX fourth review dive impressions represents our an XXXX admittedly metrics did support performance, this. will growth quarter meet in first and I X We of fourth our quarter I months then full to early story into XXXX believe of year growth the will share the quarter Today, not and our expectations. the the anomaly from which first
was year the revenue. XXXX revenue for an million reported $XX.X $XX.X net First, year XXXX. represents for full XX% Net full from XXXX million, increase which the
net XXXX the Our reflects areas. in following key revenue improvements
for full full increase a Twirla for XXXX. factory year the First, XXXX. full sales cycles, total by wholesalers of demand. Twirla XXXX demand from by as was our XXX,XXX XXXX XXX% cycles, XXX,XXX increase the was from year full the a XXX% year Symphony Twirla reported reported total year as
factory full were the XXXX, of Twirla year For sales XXX,XXX.
believe demand our parties third not for scope to the or our demand channels of retail from non-retail we total Symphony IQVIA. numbers therefore, prescription factory channels. the like receive reminder, retail were a in and do are the closely all And demand non-retail As broader the all sales sales or Twirla sales. include reported The more represents we wholesalers factory across
growth all our key components factory Net overall plan. of revenue, sales demand are and
to growth. with operating are simultaneously the We managing our align expenses supporting
$XX.X year once decrease managing the As from million, XXXX. our expenses you'll were reported for which we XXXX. year again spending disciplined for XX% represents think in see million results, full full from $XX.X we XXXX, the in Operating our were a
decreased these focuses our of efficient. partnerships, XXX%, company leveraging business by while as over the plan net XX%. while is revenue expenses external Comparing primarily our have the a has In that key against full commercial and XXXX, reengineering year infrastructure year our represented results on nearly lean full view, full the year grown year operating results to keeping XXXX full attributed metrics our internal
the quarter our the performance. fourth new We performance we're net XXXX for can the a was a of decrease remain said, XXXX. lean our confident strong XX% quarter our believe was plan XXXX third anomaly ability Next, and did business execute different XXXX. and commercial fourth why but I'll With that explain revenue to in $X.X that normal. during million confident the we XXXX, platform quarter to quarter million, produce continue this that an experience through our reported Fourth from $X.X not results
Symphony quarter Twirla quarter fourth fourth our quarter the of increased business. of due XXXX of our by was gross-to-net decrease total XXXX X for reported the XX,XXX for nonretail quarter The third in demand third second, XXXX. sales fourth in quarter XX,XXX business; first, the X% a for activity in Twirla XX,XXX, increase changes reported of XX,XXX the was an an returns total reported cycles, a reserve; our the cycles factory wholesalers, the third, to of from XXXX. mix as by from decrease XXXX increased things: Medicaid overall the primarily X% in larger as
started numbers an of XXXX. that in our was story. to because in fourth management. $X.X is employees, the of for I've quarter performance our from decision believe all to the XXXX, which in dip we expenses the XXXX We see XXXX for quarter have a forgo Operating believe rebound of first quarter of including decrease this all third million, due represents mentioned primarily quarter for growth XXXX in aberration the $X.X fourth or to the million the XX% we were bonuses already
that cycles preliminary Twirla, single we numbers achieved retail demand show highest month number January Our channel a the since launch. of in
second our be January Twirla as in launch. largest to cycles month Additionally, February demand well. appears for total since growing was
total single month While in the cycles. any as and than not February's quite February in total XXXX demand of larger as demand fourth January, was quarter both retail high was
strategic business company explore and opportunities, and end, brand, and to maximize increase externally believe that on a partnerships Twirla touch corporate To we seek and for model to is growth emphasis as its our will Twirla's we the We continue in potential. and growth maximize on both and XXXX pivotal year to updates. all internally I'll several shareholder any value. both relevant the
us, to was our First, of This Earlier Once and and especially this owed the Perceptive we our while debt for explore to significant we'd pay elimination believe support and challenging remaining opportunities, our of our Perceptive milestone grow execute month, Perceptive we to to off at thank flexibility provides again, owed debt work announced like will balance the during this Advisors. we the Advisors. sheet the on a collaboratively for embrace Twirla. continue biotechnology. with new to on partners readiness environment business to plan market us the
from our Earlier requirement. delisting stockholders' failure with compliance to due this week, equity to a we regain their announced notice NASDAQ final we received minimum
of executing to the expect to the As company's under our remain OTC is on over-to-counter while business Markets our now which by and this XX, March impact business OTC We existing XXXX, the Group is transition AGRX market, opportunities. on common continuing operated do not stock focused operations strategic explore to our plan, symbol. trading trading
XXXX, steps Affordable contraception. to We in about to access to the optimistic by contraceptives Now no-cost Care guidelines I'd remain FDA-approved about to access enable the announced recently, the talk Act. Biden-Harris January Most new all taken without to Biden being like cost. administration expanded enhance administration
and XXXX. human focus on of services the care, by labor, Biden frequently lawmakers questions widespread ongoing and department the the and to health Following January administration asked or released treasury in barriers and contraception reproductive FAQs health jointly
outlines contraceptive plans obligations reproductive which contraceptive range This comes drugs at imposing no-cost The and pathway certain covering many barriers a under devices. contraceptive federal new plans and FAQs million FDA-approved new financial coverage. no like women. ensures to law products meet pathway, approximately barriers the of by for XX a ongoing broader could and of after cost, Twirla to of for reports guidance eliminate Implementation existing insurers
promising no development XXXX our updates, January continued there believe growth. guidance, since new this we While are is for
snapshot current of situation our Before concluding I and financial provide outlook an will XXXX. for today's call, updated
You Form I'd annual our in and on comment in also year for of demonstrates can full other description And full statement a few XXXX like see of progress to to take XXXX. on our a press results financial we results, quarter financial and the minute the believe report XX-K. fourth a our which
period We continue loss out net to We closed in XXXX. $XX.X of net comparable our loss losses narrow a with XXXX million in XXXX. a full for a to of $XX.X million year
holder million million gross in We through of with raised we a exchange agreement warrants. with In $X.X of $X.X ended cash XXXX, our January hand. warrant XXXX proceeds a on
company. all to We will the continue evaluate options to finance
development credibility opportunities the a partner our other its grow development other a exploring that of ability strategic could our transactions. benefit business, business and are as We we performance opportunities business broader Additionally, is discussions. including in and Twirla strategic transaction range of solidifying Agile's business consistently potential believe and/or
stay continue to call, Twirla. will kindly today's joining call as and will everyone and we value. Twirla following you opportunities to additional Thank any and for We for us for seek to related again This conclude and we this all updates tuned explore and shareholder along. encourage Agile grow us to Therapeutics
